Skip to main content

Six-month-old cancer startup makes $166M Nasdaq debut

Almost exactly six months after emerging from stealth, cancer startup Nuvalent is hitting the public markets in a $166 million IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.